| Literature DB >> 31417264 |
Mansour Jannati1, Armin Attar2.
Abstract
This review aimed to study the role of analgesia and sedation after coronary artery bypass graft (CABG) surgery, regarding pain management, assisted respiration, overall postoperative health care, and hospitalization. Data were collected from Pubmed, Scopus, and Cochrane databases. The following terms were used for the search: "analgesia", "sedation", "coronary artery bypass grafting", CABG", and "opioids". Articles between the years 1988 and 2018 were evaluated. Several opioid and non-opioid analgesics used to relieve surgical pain are regarded as critical risk factors for developing pulmonary and cardiovascular complications in all kinds of thoracic surgery, especially CABG procedures. Effective pain management in post-CABG patients is largely dependent on effective pain assessment, type of sedatives and analgesics administered, and evaluation of their effects on pain relief. A significant challenge is to determine adequate amounts of administered analgesics and sedatives for postoperative CABG patients, because patients often order more sedatives and analgesics than needed. The pain management process is deemed successful when patients feel comfortable after surgery, with no negative side effects. However, postoperative pain management patterns have not included many modern methods such as patient-controlled analgesia, and postoperative pain management drugs are still limited to a restricted range of opioid and non-opioid analgesics.Entities:
Keywords: ICU; analgesia; coronary artery bypass grafting (CABG); opioids; sedation
Year: 2019 PMID: 31417264 PMCID: PMC6592068 DOI: 10.2147/TCRM.S195267
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Analgesics and sedatives for pain treatment after coronary surgery
| Analgesics and sedatives | Mechanism of action | Adverse effects |
|---|---|---|
| Opioids | Different opioid analgesics vary | Respiratory sedation, depression, nausea and vomiting, gastrointestinal atony, and pruritus; opioid-induced tolerance and hyperalgesia |
| Gabapentin | Gabapentin reduces neurotransmitter release via a calcium-dependent mechanism or NMDA-mediated decrease in the glutamate-releasing mechanism | |
| Paracetamol | Acts via inhibiting prostaglandin synthesis, by increasing descending serotonergic impulses that are antinococeptive, or via indirectly activating cannabinoid CB1 receptors | Increased risk of gastrointestinal bleeding and a small increase in systolic blood pressure |
| NSAIDs | Cyclooxygenase inhibitors | Gastrointestinal tract effects, blood pressure elevation, and development of congestive heart failure |
| Ketamine | Works as a non-competitive antagonist of NMDA receptors | Psychotomimetic adverse effects |
| Magnesium | Analgesic effects related to the calcium channel antagonist effect and blocking the NMDA channel | Hypotension |
| Propofol | Hypotension | |
| Dexmedetomidine | Stimulates α2-adrenoreceptors in the central nervous system | Hypotension and bradycardia |
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; NMDA, N-methyl-d-aspartate.